弥漫大B细胞淋巴瘤患者血清VEGF、β_2-MG、TRAF6、Bcl-6水平对预后的影响  

The relationships between serum level of VEGF,β_2-MG,TRAF6,Bcl-6 in diffuse large B cell lymphoma with the prognosis

作　　者：何吉琼 李亚琼[1] 杨丽华[1] 乔爱国[1] 

机构地区：[1]四川省达州市中心医院血液科,635000

出　　处：《疑难病杂志》2015年第7期708-711,共4页Chinese Journal of Difficult and Complicated Cases

摘　　要：目的观察血清血管内皮生长因子(VEGF)、β_2微球蛋白(β_2-MG)、TNF受体关联因子6(TRAF6)及B细胞淋巴瘤因子-6(Bcl-6)水平对弥漫大B细胞淋巴瘤(DLBCL)患者的预后影响。方法选取2012年4月—2014年4月收治的51例弥漫大B细胞淋巴瘤初治患者,记录不同性别、年龄、是否侵犯纵隔、是否合并B组症状、乳酸脱氢酶水平及不同治疗效果的患者例数,分析血清VEGF、β_2-MG、TRAF6及Bcl-6水平对患者预后的影响。结果51例DLBCL患者中,VEGF高水平25例,β_2-MG高水平39例,TRAF6阳性11例,Bcl-6阳性8例。不同性别、不同年龄、是否侵犯纵隔、是否合并B组症状、不同临床分期、乳酸脱氢酶是否升高与血清VEGF、β_2-MG高水平及TRAF6、Bcl-6阳性患者例数之间差异不具有统计学意义(P均>0.05),但β_2-MG、TRAF6、Bcl-6高水平/(阳性)与低水平/(阴性)患者治疗效果差异具有统计学意义(x^2=10.455、7.913、5.004,P=0.001、0.005、0.025)。低危组VEGF、β_2-MG、TRAF6及Bcl-6值分别为(446.31±38.82)ng/ml、(194 3.15±178.28)ng/ml、(1.27±0.60)ng/ml、(13.68±7.32)ng/nml,高危组分别为(482.31±37.71)ng/ml、(2 128.32±243.12)ng/ml、(1.72±0.83)ng/ml、(21.93±6.85)ng/ml,2组相比差异均具有统计学意义(t=3.348、3.040、2.174、4.150,P=0.002、0.004、0.035、0.000)。结论弥漫大B细胞淋巴瘤患者的血清VEGF、β_2-MG、TRAF6、Bcl-6水平有助于判断患者预后,对提高DLBCL患者疗效及制定个体化治疗方案具有重要的指导意义,值得在临床上予以推广。Objective To observe the effect of serum vascular endothelial growth factor （ VEGF） , beta 2 microglobu-lin（β2-MG）, TNF receptor associated factor 6 （TRAF6） and B cell lymphoma factor-6 （Bcl-6） level in diffuse large B cell lymphoma （ DLBCL） patients’ prognosis.Methods From 2012 April to 2014 April, 51 cases of diffuse large B cell lympho-ma were enrolled, records of different gender, age, whether involved the mediastinum, whether combined with group B symp-toms, lactate dehydrogenase level and the effect of different treatments were recorded, analysis serum vascular endothelial growth factor （ VEGF） ,β2-MG, TRAF6 and Bcl-2 serum level on the prognosis of the patients.Results In the 51 cases of DLBCL patients, high level of VEGF were found in 25 cases,β2-MG high level in 39 cases, TRAF6 was positive in 11 cases, Bcl-6 were positive in 8 cases.Different gender, different age, mediastinal invasion, with B symptoms, clinical stage, lactate dehydrogenase increased or not had no relation with the number of patient with serum VEGF andβ2-MG, TRAF6, Bcl-6 high level （all P 〉0.05）, but β2-MG, TRAF6, Bcl-6 high level/positive and low level/（negative） therapeutic effect difference has statistical significance （χ2 =10.455,χ2 =7.913,χ2 =5.004, P =0.001, P =0.005, P =0.025）.Low risk group’s VEGF,β2-MG, TRAF6 and Bcl-6 were （446.31 ±38.82） ng/ml, （194 3.15 ±178.28） ng/ml, （1.27 ±0.60） ng/ml, （13.68 ±7.32） ng/ml, respectively, the high-risk group were （482.31 ±37.71） ng/ml, （2 128.32 ±243.12） ng/ml, （1.72 ±0.83） ng/ml, （21.93 ±6.85） ng/ml,respectively, 2 groups’ difference has statistical significance （ t =3.348, t=3.040, t =2.174, t =4.150, P =0.002, P =0.004, P =0.035, P =0.000）.Conclusion The serum VEGF,β2-MG, TRAF6, Bcl-6 level in diffuse large B cell lymphoma patients are helpful to judge the prognosis and to improve the treat-ment of DLBCL and determine individualized treatment plan, which has important guiding significance.

关 键 词：弥漫大B细胞淋巴瘤 内皮生长因子 β2 微球蛋白 TNF受体关联因子6 B细胞淋巴瘤因子-6 预后 

分 类 号：R733.1[医药卫生—肿瘤]